
AirSculpt Technologies, Inc. (AIRS) Market Cap
AirSculpt Technologies, Inc. has a market capitalization of $180.6M.
Financials based on reported quarter end 2025-12-31
Price: $2.56
βΌ -0.04 (-1.54%)
Market Cap: 180.60M
NASDAQ Β· time unavailable
CEO: Yogesh Jashnani
Sector: Healthcare
Industry: Medical - Care Facilities
IPO Date: 2021-10-29
Website: https://www.elitebodysculpture.com
AirSculpt Technologies, Inc. (AIRS) - Company Information
Market Cap: 180.60M Β· Sector: Healthcare
AirSculpt Technologies, Inc., together with its subsidiaries, focuses on operating as a holding company for EBS Intermediate Parent LLC that provides body contouring procedure services in the United States. It offers custom body contouring using its AirSculpt procedure that removes unwanted fat in a minimally invasive procedure. The company provides fat removal procedures across treatment areas; and fat transfer procedures that use the patient's own fat cells to enhance the breasts, buttocks, hips, or other areas. Its body contouring procedures also include the Power BBL, a Brazilian butt lift procedure; the Up a Cup, a breast enhancement procedure; and the Hip Flip, an hourglass contouring procedure. As of March 10, 2022, it operated 19 centers across 15 states. AirSculpt Technologies, Inc. was founded in 2012 and is headquartered in Miami Beach, Florida.
Analyst Sentiment
Based on 2 ratings
Analyst 1Y Forecast: $6.00
Average target (based on 3 sources)
Consensus Price Target
Low
$6
Median
$6
High
$6
Average
$6
Potential Upside: 134.4%
Price & Moving Averages
Related Companies in Healthcare
Fundamentals Overview
π AI Financial Analysis
Powered by StockMarketInfo"AIRS (based on results through 2025-12-31) reported revenue of $33.44M and net income of $1.28M, for EPS of $0.0186. Net margin was ~3.8% (net income / revenue). Free cash flow was $3.35M on operating cash flow of $9.82M with capital expenditures of -$6.47M. On the balance sheet, AIRS had $187.30M in total assets versus $99.59M in total liabilities, resulting in $87.71M of equity. Net debt was $24.54M, indicating moderate leverage relative to equity. From a fundamentals perspective, profitability is positive but modest, with a thin net margin that suggests sensitivity to costs and operating mix. Cash flow generation appears credible: despite meaningful capex, the company still produced positive FCF, supporting financial flexibility. Leverage is not extreme, but the balance sheet shows liabilities exceeding assetsβ net buffer, so resilience depends on sustained cash generation. Shareholder returns are being driven primarily by price appreciation rather than distributionsβdividends paid are $0 in the cash-flow data (the last listed dividend was in 2022). The stockβs strong 1-year gain (+50.95%) and YTD move (+71.35%) materially increase total shareholder return, despite a sharp 6-month decline (-60.18%). Valuation details (e.g., P/E, FCF yield) were not provided in the dataset, limiting precision in valuation scoring."
Revenue Growth
Only current-period revenue ($33.44M) is provided; YoY growth rates and trend are not available, so growth stability cannot be quantified.
Profitability
Net income of $1.28M implies a ~3.8% net marginβpositive profitability, but relatively low versus stronger margin peers; EPS is $0.0186.
Cash Flow Quality
Operating cash flow of $9.82M and positive free cash flow of $3.35M (after $6.47M capex) indicate the business can convert earnings into cash, though FCF scale is modest.
Leverage & Balance Sheet
Net debt of $24.54M versus equity of $87.71M suggests moderate leverage. Total assets ($187.30M) exceed total liabilities ($99.59M), supporting balance-sheet resilience.
Shareholder Returns
Total shareholder value appears driven mainly by capital appreciation: +50.95% (1Y) and +71.35% (YTD). Dividends in the period are $0 and no buybacks are provided, so contribution from distributions is limited.
Analyst Sentiment & Valuation
Price target consensus is $6 (target high/low all $6) versus the current price of $3.17, but valuation multiples (P/E, FCF yield) are not provided, restricting valuation assessment.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.
AIRS reported Q4 2025 results marked by continued revenue contraction but clear profitability progress. Gross margin expanded to ~59% (about +200 bps) and adjusted EBITDA rose to $2.5M (7.4% margin), up $0.6M YoY with ~+280 bps margin expansionβdriven by lower costs and operational leverage, despite case volume weakness. Management attributes the turnaround trajectory to actions initiated in Q4 2025: scaling skin tightening to all centers, running a skin excision (skin removal) pilot that already produced >100 surgeries in Q4 and is expected to ramp in 2026, and tightening marketing execution (connected TV, influencer engagement, conversion flow improvements). Same-store sales improved from down 22% at the start of 2025 to positive in Feb 2026, with March also favorable, and Q1 2026 guided flat. For FY 2026, revenue is expected at $151M-$157M and adjusted EBITDA $15M-$17M, while the company targets net debt leverage below 2.5x via refinance.
Growth Catalysts
- Rolled out stand-alone skin tightening to all centers in 2H 2025
- Skin excision pilot (skin removal) completed >100 surgeries in Q4 2025; ramp expected in 2026 across all locations
- GLP-1-adjacent service expansion (skin tightening/skin removal) supporting fat removal/body contouring workflows
- Enhanced marketing strategy beginning Q4 2025: connected TV, increased influencer engagement, focused campaigns for skin tightening and skin removal, improved website conversion flows, and optimized spend to higher-value audiences
- Improved patient financing options to drive conversion while maintaining full upfront payment policy
Business Development
- No named external partners/customers/vendors disclosed; supplier network referenced for helium plasma
Financial Highlights
- Q4 2025 revenue: $33.4M, down ~15% YoY; same-store revenue down 16% YoY (lower case volume amid challenging consumer spending)
- Gross margin expansion: cost of services decreased $3.1M to $13.7M (down 18% YoY) driving ~+200 bps to ~59% gross margin
- SG&A: ~$18.2M in quarter, down ~$5M YoY (cost initiatives in 2025)
- Adjusted EBITDA: $2.5M (7.4% of revenue), up $0.6M YoY with +280 bps margin expansion
- Full-year 2025 revenue: $151.8M, down ~15.8% vs 2024; adjusted EBITDA: ~$15M, margin ~10% vs ~12% in 2024 (down ~200 bps)
- Financing usage: ~50% of patients using financing (no recourse to AIRS for third-party financed patients; AIRS receives full upfront payment)
- 10-K delay driver: intercompany reconciliation matter and broader review including ASC 842 lease accounting; recorded immaterial prior-year balance changes only
Capital Funding
- Debt paydown: repaid >$30M over last 5 quarters; $19M in 2025 ($14M term loan, $5M revolver)
- Cash: $8.4M as of Dec 31, 2025
- ATM activity: raised additional $14.8M from at-the-market facility in Q1
- Additional debt principal paydown after ATM: paid down $11M principal in the period
- Gross debt at year-end: $56M
- Leverage/covenants: leverage ratio below 3x at year-end; in compliance with all covenants; target refinance to keep net debt leverage ratio <2.5x
Strategy & Ops
- Strategic exit: exited the only clinic outside North America (to streamline operations)
- Operational cost discipline: generated over $4M in annualized savings in 2025; outlook references annualization of '25 cost actions
- Simplification of business and selective reinvestment into growth initiatives and talent
- Talent additions: in Q1 (2026) added experienced executives across finance, legal, and operations for multiunit operations management
- De novo (new center) guidance: no de novos contemplated in 2026 guidance; focus is revenue growth in existing base
Market Outlook
- Q1 2026 same-store sales expected to be flat; described as midpoint of previously provided revenue range
- FY 2026 revenue guidance: $151M to $157M (midpoint implies ~3% comparable growth excluding London from 2025; London contributed 1% to comps in 2025)
- FY 2026 adjusted EBITDA guidance: $15M to $17M (outlook assumes improved revenue growth and annualization of 2025 cost actions)
Risks & Headwinds
- Challenging consumer spending environment contributing to lower case volume (Q4 revenue down ~15%, same-store down 16%)
- Seasonality/back-end loading concern acknowledged by management: need consistent execution to hit numbers (no specific numeric mitigation provided)
- Helium plasma supply constraint: a meaningful portion of global supply offline due to Iran conflict; helium plasma suppliers monitored and managed accordingly
Sentiment: MIXED
Note: This summary was synthesized by AI from the AIRS Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.





